Eurofins Scientific SE

ERFSFOTCHealthcare● Active

$72.60

$-3.39(-4.46%)

Market Cap$12.7B

P/E Ratio—

52W High$86.2

52W Low$63.96

Avg Volume4K

Open$76.35

Beta0.85

Free Cash Flow Financials Revenue

Eurofins Scientific SE (ERFSF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ERFSF · free cash flow · updated Jun 9, 2026

Core FCF metrics

ERFSF · FCF · TTM · margin & CAGR

Free cash flow was $534.8M for FY2025 (fiscal year ending 2025-12-31), down 32.3% year-over-year The FCF margin was 7.3%. Five-year CAGR stands at -9.2%.

FY2025 Free Cash Flow$534.8M▼ -32.3% YoY

Trailing 12M (TTM)$1.35Btrailing 4 quarters sum

FCF Margin7.3%$534.8M ÷ revenue

3-Year CAGR+4.0%FY2022 → FY2025

5-Year CAGR-9.2%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ERFSF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$1.29B(760M)$534.8M▼ 32.3%7.3%

FY2024$1.32B(528M)$790.5M▲ +69.0%11.4%

FY2023$1.02B(550M)$467.8M▼ 1.7%7.2%

FY2022$1.14B(660M)$476.1M▼ 51.9%7.1%

FY2021$1.51B(520M)$990.3M▲ +14.1%14.7%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ERFSF · P/FCF · FCF yield · FCF per share

Eurofins Scientific SE (ERFSF) trades at a FCF yield of 3.57% and a price-to-free-cash-flow ratio of 9.7x. FCF per share stands at $7.48, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

3.57%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$7.48

TTM FCF ÷ Shares Outstanding

Price / FCF

x9.7

Share Price ÷ FCF per Share

EV / FCF (TTM)

x39.5

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

ERFSF · cash flow statement · operating / investing / financing

For FY2025, Eurofins Scientific SE generated $1.29B in operating cash flow and spent 760M in capital expenditures, yielding $534.8M in free cash flow.

Operating Activities

+$1.29B

Cash from core business operations

2025-12-31

Investing Activities

−$1.09B

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$13.0M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($1.29B) − |CapEx| (760M) = FCF ($534.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ERFSF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Eurofins Scientific SEYOU

ERFSF

$534.8M-32.3%7.3%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Eurofins Scientific SE (ERFSF) reported free cash flow of $534.8M for FY2025 (fiscal year ending 2025-12-31), down 32.3% year-over-year. The FCF margin was 7.3%.

Based on available data, Eurofins Scientific SE has maintained positive free cash flow for at least 15 fiscal year(s). FCF peaked at $990.3M in FY2021. The 5-year CAGR stands at -9.2%.

Eurofins Scientific SE's FCF yield is 3.57% and price-to-FCF ratio is 9.7x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ERFSF free cash flow · 8 questions

Eurofins Scientific SE free cash flow was $534.8M for FY2025, down 32.3% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $1.35B.

ERFSF free cash flowERFSF FCFERFSF FCF 2025ERFSF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Eurofins Scientific SE · Eurofins Scientific SE SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026